Interestingly, DPP-4 has been implicated in many chronic conditions with recent findings showing that the inhibition of DPP-4 activity can substantially reduce obesity and obesity-related inflammation [44] and that pre-treatment with DPP-4 inhibitors in obesity or diabetic condition can protect body organs from these conditions [45]. This evidence concerns the gene DPP4 and obesity due to melanocortin 4 receptor deficiency.